Emergent raises guidance on increased BioThrax delivery

Emergent BioSolutions Inc. (NYSE:EBS) raised its 2010 revenue guidance to $275-$300 million from $235-$255 million after CDC modified the company's procurement contract for its BioThrax anthrax vaccine. The modification increases the number of BioThrax doses that Emergent can deliver into the Strategic National Stockpile during 2010. The CDC contract expires in 3Q11; however, the company is in negotiations for a new three-year contract, which it hopes to disclose by year end. Emergent was up $1.18 to $18.93 on Tuesday. ...